Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

L-DOPA for Parkinson's disease-a bittersweet pill

Lane, Emma L. 2019. L-DOPA for Parkinson's disease-a bittersweet pill. European Journal of Neuroscience 49 (3) , pp. 384-398. 10.1111/ejn.14119

PDF - Accepted Post-Print Version
Download (295kB) | Preview


3,4‐dihydroxy‐L‐phenylalanine (L‐DOPA) is the gold standard treatment for Parkinson's disease. It has earned that title through its highly effective treatment of some of the motor symptoms in the early stages of the disease but it is a far from perfect drug. The inevitable long‐term treatment that comes with this chronic neurodegenerative condition raises the risk significantly of the development of motor fluctuations including disabling L‐DOPA‐induced dyskinesia. Being unsurpassed as a therapy means that understanding the mechanisms of dyskinesia priming and induction is vital to the search for therapies to treat these side effects and allow optimal use of L‐DOPA. However, L‐DOPA use may also have consequences (positive or negative) for the development of other interventions, such as cell transplantation, which are designed to treat or repair the ailing brain. This review looks at the issues around the use of L‐DOPA with a focus on its potential impact on advanced reparative interventions.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Pharmacy
Publisher: Wiley
ISSN: 0953-816X
Date of First Compliant Deposit: 1 October 2018
Date of Acceptance: 30 July 2018
Last Modified: 17 Aug 2019 02:06

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item